Understanding Tysabri and PML: What Monitoring Involves

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Legacy Context and Transition to Legal Awareness

If you or a loved one is taking Tysabri, understanding the symptoms of progressive multifocal leukoencephalopathy (PML) is critical for early detection. For decades, the medical community has recognized that certain therapies carry rare but serious risks, and ongoing monitoring has become a standard part of care. This page explains the clinical workup and testing involved in diagnosing PML, helping you distinguish symptoms from other conditions.

Find Out If You Qualify for Compensation →

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Florida who have developed PML after Tysabri exposure, understanding the medical evidence and legal time limits is critical. The prescribing information for Tysabri contains a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data showing that PML occurs in patients receiving Tysabri, with three established risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label emphasizes that these factors "should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically presents with progressive neurological deficits, including cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The clinical course is often devastating, with most cases leading to severe disability or death. The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist, which prevents immune cells from crossing the blood-brain barrier. This immunosuppressive effect within the central nervous system allows latent JC virus to reactivate and cause lytic infection of oligodendrocytes.

Regulatory Warnings and Monitoring Programs

The adequacy of warnings regarding Tysabri and PML is a central issue in legal claims. The FDA-approved label includes a boxed warning and mandates that Tysabri be prescribed only through the TOUCH Prescribing Program, a restricted distribution system designed to monitor patients for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Under this program, healthcare providers must evaluate patients at specified intervals, including three months after the first infusion, six months after the first infusion, and every six months thereafter, as well as for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Providers must also report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients received sufficient information about PML risk before starting treatment, particularly regarding the cumulative risk over time.

Statute of Limitations for Tysabri Claims in Florida

For settlement-related considerations, affected patients in Florida should be aware that legal claims involving Tysabri and PML typically fall under product liability or medical malpractice theories. The statute of limitations for such claims in Florida is generally two years from the date the injury was discovered, or from the date when the injury should have been discovered with reasonable diligence. This timeline is critical because PML symptoms may develop gradually, and the connection to Tysabri may not be immediately apparent. The timeline between Tysabri exposure and documented harm can vary widely. PML risk increases with longer treatment duration, especially beyond two years, but cases have been reported after shorter exposure. Once symptoms appear, diagnosis may be delayed due to the nonspecific nature of early neurological signs. The TOUCH program requires ongoing monitoring, but PML can still occur despite adherence to surveillance protocols. Patients who have developed PML after Tysabri treatment should seek legal counsel promptly to evaluate their claims within Florida's statute of limitations. Medical records documenting Tysabri use, PML diagnosis, and the timing of symptom onset are essential for establishing the exposure-harm timeline. Settlement amounts in Tysabri-related PML cases have varied based on factors such as the severity of disability, medical expenses, lost income, and the strength of evidence regarding inadequate warnings. The FDA-mandated boxed warning and TOUCH program may be cited by defendants as evidence of adequate risk communication, but plaintiffs may argue that these measures were insufficient to prevent harm in their specific circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Florida?

In Florida, the statute of limitations for product liability or medical malpractice claims related to Tysabri and PML is generally two years from the date the injury was discovered, or from the date when the injury should have been discovered with reasonable diligence. It is crucial to consult an attorney promptly to avoid missing this deadline.

What are the risk factors for developing PML while on Tysabri?

The three established risk factors for PML in Tysabri patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the FDA-approved prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.